Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Kamada Ltd. (NASDAQ:KMDA)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $8.04 and traded as low as $7.08. Kamada shares last traded at $7.09, with a volume of 50,074 shares changing hands.

Analyst Ratings Changes

KMDA has been the subject of a number of research reports. William Blair set a $15.00 price objective on Kamada in a report on Tuesday. Weiss Ratings downgraded Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Wall Street Zen cut shares of Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Benchmark reiterated a “buy” rating on shares of Kamada in a report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kamada presently has an average rating of “Buy” and a consensus price target of $13.00.

Kamada Stock Performance

The company has a fifty day moving average price of $7.44 and a two-hundred day moving average price of $8.05. The company has a market cap of $403.15 million, a P/E ratio of 20.03, a PEG ratio of 0.65 and a beta of 0.85.

Kamada (NASDAQ:KMDA) last released its earnings results on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). The company had revenue of $45.24 million for the quarter, compared to the consensus estimate of $46.72 million. Kamada had a return on equity of 7.73% and a net margin of 11.21%. Research analysts anticipate that Kamada Ltd. will post 0.44 EPS for the current year.

Hedge Funds Weigh In On Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new position in Kamada during the first quarter worth $206,000. NewEdge Advisors LLC increased its stake in shares of Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 28,165 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Kamada during the 1st quarter worth about $497,000. Jane Street Group LLC bought a new stake in shares of Kamada in the 1st quarter valued at about $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Kamada in the 2nd quarter valued at about $472,000. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.